Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
2010-07-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures
NCT00323609
FREE Study - Fracture Reduction Evaluation
NCT00211211
Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures
NCT01175278
Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures
NCT01383616
Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs
NCT01871519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Kiva VCF Treatment System
Vertebral augmentation
Vertebral augmentation for one or two osteoporotic vertebral compression fractures
Balloon Kyphoplasty
Vertebral augmentation
Vertebral augmentation for one or two osteoporotic vertebral compression fractures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vertebral augmentation
Vertebral augmentation for one or two osteoporotic vertebral compression fractures
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient has a score on the back pain visual analog scale (VAS) of ≥70 mm after 2 to 6 weeks of conservative care OR a VAS of ≥ 50 mm after 6 weeks of conservative care
3. The patient has an Oswestry Disability Index (ODI) score of ≥ 30%
4. The patient has radiographic evidence of one or two (1-2) A 1.1, A 1.2, A 1.3. fractures as classified by the AO Spine Fracture classification, due to primary or secondary osteoporosis in the thoracic and / or lumbar spine. Note that patients are eligible if they have had treatment of or healed VCF(s) at any non-index level
5. The patient has central pain over the spinous process(es) upon palpation at the Index level(s)
6. The Index fracture(s) is / are acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI
7. The Index fracture(s) has / have failed conservative care of at least 2 weeks but no longer than 6 months
8. The Index fracture(s) shows radiographic evidence of at least 5% vertebral collapse
9. The pedicle identified for access to the index fracture has a diameter that is ≥ 6 mm
10. The patient is mentally capable and willing to sign a study-specific informed consent as documentation of the informed consent process prior to any study procedures
11. The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments
Exclusion Criteria
2. The index fracture(s) has / have known tumor involvement
3. The index fracture(s) is/are diagnosed as an osteonecrotic fracture(s) by the treating physician
4. The Index fracture(s) is a/are translational force fracture(s) (A2.1, 2.2, 2.3)
5. The index fracture(s) is a/are burst fracture(s) (A 3.3., B or C type) or pedicle fracture(s) with posterior cortical wall disruption
6. The index fracture(s) has / have posterior vertebral wall displacement occupying more than 20% of the cross sectional area of the spinal canal
7. The index fracture(s) has / have severe deformity with reduction of \>75% in any height and accompanying area, using adjacent level as comparison
8. The index level(s) has / have undergone previous surgical treatment for a vertebral body compression fracture or other surgical procedure at the index level(s)
9. Angulation of index fracture(s) makes treatment with Kiva System impossible (at discretion of surgeon)
10. The pedicle identified for access to the index fracture has a diameter less than 6 mm
11. The patient has Paget's disease
12. The patient has a BMI \> 35
13. The patient has uncontrolled diabetes as characterized by hemoglobin HbA1c \>7% and/or blood sugar \>180mg/dL
14. The patient has severe cardiopulmonary deficiencies
15. The patient has myelopathy
16. The patient is on long-term steroid therapy (steroid dose ≥ 30 mg /day for \> 3 months)
17. A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy (with a threshold for normal being INR ≤ 1.5, PTT within lab normal range, and platelet count \> 100,000)
18. The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level(s) to be treated;
19. The patient has neurologic symptoms or deficits or radiculopathy related to the VCF
20. The patient has pain based on clinical diagnosis of herniated nucleus palposus or severe spinal stenosis (progressive weakness or paralysis)
21. The patient has indications of instability related to the index fracture (≥ 30 degrees of kyphosis, translation \>4mm, interspinous process widening, \> Grade 1 spondylolisthesis and/or \> 25 degrees of scoliosis if the index level is included in the curve)
22. The patient has planned spine surgery for any disorder during or up to 30 days after the study treatment
23. The patient has had spine surgery for any disorder in the 30 days prior to enrollment
24. The patient has a documented active systemic or local infection, such as osteomyelitis or discitis, with a WBC \> 15.0 x 10\^3/µL and a temperature \> 101.5°F
25. The patient has a known allergy to the investigational device materials and / or acrylics / polymethylmethacrylate (PMMA) or a hypersensitivity to monomers
26. The patient has been diagnosed with hemorrhagic diathesis
27. The patient has uncontrolled psychiatric illness or severe dementia
28. The patient has a baseline back pain visual analog scale (VAS) of \<50 mm if patient has at least 6 weeks of conservative care or \<70 mm if patient has 2-6 weeks conservative care
29. The patient has a baseline Oswestry Disability Index (ODI) score of \<30%
30. The patient is currently on anti-cancer therapy or anti-HIV therapy
31. Patient has autoimmune or inflammatory rheumatic disease
32. Patient's life expectancy is less than the study duration or undergoing palliative care
33. The patient is known to be a current alcohol or drug abuser
34. The patient is known to be involved in medical litigation including Workmen's Compensation
35. The patient is a prisoner
36. The patient is participating in another investigational study that has a potential for effect to the study treatment or the study endpoints
37. The patient is pregnant or considering getting pregnant during study participation
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benvenue Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven R. Garfin, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Diego, CA
Sean M. Tutton, MD, FSIR
Role: PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CORE Orthopaedic Medical Center
Encinitas, California, United States
El Camino Hospital
Mountain View, California, United States
Radiological Associates of Sacramento
Sacramento, California, United States
St. Mary's Spine Center
San Francisco, California, United States
Radiology Imaging Associates
Englewood, Colorado, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Evanston Hospital
Evanston, Illinois, United States
Adventist Hospital
Hinsdale, Illinois, United States
Spine Institute of Louisiana
Shreveport, Louisiana, United States
Mayo Clinic-Rochester
Rochester, Minnesota, United States
Sierra Regional Spine Institute
Reno, Nevada, United States
Clinical Radiology of Oklahoma
Edmond, Oklahoma, United States
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
CHC Saint Joseph
Liège, , Belgium
Toronto Western Hospital
Toronto, Ontario, Canada
Montreal General Hospital
Montreal, Quebec, Canada
CHU Amiens Sud
Amiens, , France
Universitatsklinikum Bonn
Bonn, , Germany
Klinikum Ernst von Bergmann gGmbH
Potsdam, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Beall DP, Coe JD, McIlduff M, Bloch D, Hornberger J, Warner C, Tutton S. Serious Adverse Events Associated with Readmission Through One Year After Vertebral Augmentation with Either a Polyetheretherketone Implant or Balloon Kyphoplasty. Pain Physician. 2017 Sep;20(6):521-528.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BEN005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.